AAX Biotech key facts
as of Oct 2026- Developer of antibody technologies intended for cancer, autoimmune diseases, and neurological diseases.
- AAX Biotech is valued at approximately $4.1M as of Oct 2026 (last reported valuation).
- It has raised $1.2M; the latest was Later Stage VC in Feb 2026.
- Notable investors include Jinderman & Partners, DRIVE ( KI Innovations Business Incubator), HJKK Didrikson, Karolinska Institutet, Karolinska Institutet Holding — 12 tracked in total.
- Status: Privately Held (backing).
AAX Biotech's last reported valuation, Oct 2024. Nothing priced has surfaced since.
- ·The complete investor list: 12 names
- ·Watch AAX Biotech: the Monday email on marks, rounds and moves
AAX Biotech funding rounds
No funding rounds for AAX Biotech are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs AAX Biotech
12+AAX Biotech valuation
AAX Biotech's last reported valuation was $4.1 million in Oct 2024. No priced round, secondary trade or fund mark has surfaced since.
AAX Biotech investors
12 investors are on record for AAX Biotech, including Jinderman & Partners, DRIVE ( KI Innovations Business Incubator), HJKK Didrikson and Karolinska Institutet.
About AAX Biotech
Developer of antibody technologies intended for cancer, autoimmune diseases, and neurological diseases. The company's technology provides improved antibody characterization through high-resolution, high-throughput epitope mapping, helping healthcare professionals by making it easy to produce antibody-based medicines and enabling other antibody-developing companies to excel in solving their technical difficulties.
- Sector
- Healthcare
- HQ
- Stockholm, Sweden
- Founded
- 2020
- Employees
- 9
- Website
- aaxbiotech.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.